drugset / Trial / NCT00477087
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effect of the combination of mitoxantrone and granulocyte-macrophage colony stimulating factor (GM-CSF) on progression-free survival (PFS) and overall survival (OS), in patients with hormone-refractory prostate cancer.
Timeline
- Start
- 2006-07
- Primary completion
- 2009-10
- Completion
- 2010-01
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GM-CSF | Protein / enzyme biologic | 250 ug/m2 | Subcutaneous |
| Subject | Mitoxantrone | Small molecule | 14 mg/m2 | — |